Journal article
Impact of pre-stroke sulphonylurea and metformin use on mortality of intracerebral haemorrhage
TY Wu, BCV Campbell, D Strbian, N Yassi, J Putaala, T Tatlisumak, SM Davis, A Meretoja, DF Hanley, K Butcher, B Gregson, S Davis, KR Lees, P Lyden, K Muir, T Steiner, S Mayer
European Stroke Journal | SAGE PUBLICATIONS LTD | Published : 2016
Abstract
Introduction: Few proven therapies for intracerebral haemorrhage exist. Preliminary observational evidence suggests that sulphonylurea and metformin may be protective in ischaemic stroke. We assessed the association of pre-intracerebral haemorrhage sulphonylurea and metformin use on outcome in diabetic patients. Methods: We merged datasets from the consecutive single-centre Helsinki ICH Study, the intracerebral haemorrhage arm of the Virtual International Stroke Trials Archive (VISTA-ICH) and the Royal Melbourne Hospital ICH Study. Logistic regression adjusting for known predictors of intracerebral haemorrhage outcome (age, sex, baseline Glasgow Coma Scale, National Institutes of Health Stro..
View full abstractGrants
Awarded by Neurological Foundation of New Zealand
Awarded by National Health and Medical Research Council of Australia
Awarded by National Heart Foundation
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: TYW is supported by grants from the Neurological Foundation of New Zealand (grant number 1313-CF) and Royal Melbourne Hospital Neuroscience Foundation; BCVC receives research support from the National Health and Medical Research Council of Australia (GNT1043242, GNT1111972, GNT1113352), National Heart Foundation (Future Leaders Fellowship 100782); TT is supported by the Helsinki University Central Hospital and Sahlgrenska University Hospital grants for ICH research; SMD is supported by grants from the National Health and Medical Research Council (Australia). NY is supported by the National Health and Medical Research Council (Australia) and Australian Research Council. AM is supported by grants from National Health and Medical Research Council (Australia), Academy of Finland and the Finnish Medical Foundation.